0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Thioridazine-Induced Cholestasis

Maurice Barancik, MD; Lloyd L. Brandborg, MD; Martin J. Albion, MD
JAMA. 1967;200(1):69-70. doi:10.1001/jama.1967.03120140127031.
Text Size: A A A
Published online

SINCE chlorpromazine was introduced in 1952, the list of phenothiazines causing cholestasis has grown considerably. In addition to chlorpromazine, other icterogenic phenothiazines are promazine, prochlorperazine, mepazine, and trifluoperazine.1 This complication occurs in less than 1% of individuals taking phenothiazines.1,2

Phenothiazine cholestasis is benign and almost always remits when the offending drug is discontinued.1-5 In fact there may be remission of jaundice while the drug is being administered.4 Cases are reported in which there was progression of the condition to xanthomatous biliary cirrhosis.1-3,5,6 Cohen has recently stated that "an unequivocal case of jaundice due to thioridazine is not known."2

In 1959, Block7 reported jaundice in a 79-year-old woman who was administered modest doses of thioridazine for a nine-month period. At the end of that time, her bilirubin level was 1.2 mg/100 ml and her transaminase level was elevated. Within two weeks of stopping thioridazine,

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();